Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy?
Drug Discov Ther
; 14(3): 143-144, 2020 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: covidwho-612733
ABSTRACT
In the midst of a pandemic, finding effective treatments for coronavirus disease 2019 (COVID-19) is the urgent issue. In "chronic inflammatory diseases", the overexpression of delayed rectifier K+-channels (Kv1.3) in leukocytes is responsible for the overactivation of cellular immunity and the subsequent cytokine storm. In our previous basic studies, drugs including chloroquine and azithromycin strongly suppressed the channel activity and pro-inflammatory cytokine production from lymphocytes. These findings suggest a novel pharmacological mechanism by which chloroquine, with or without azithromycin, is effective for severe cases of COVID-19, in which the overactivation of cellular immunity and the subsequent cytokine storm are responsible for the pathogenesis.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Neumonía Viral
/
Linfocitos
/
Citocinas
/
Sistemas de Liberación de Medicamentos
/
Infecciones por Coronavirus
/
Canal de Potasio Kv1.3
/
Betacoronavirus
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
Drug Discov Ther
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
Ddt.2020.03046
Similares
MEDLINE
...
LILACS
LIS